With 0.13 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.14 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.7 whereas the lowest price it dropped to was $5.36. The 52-week range on NGEN shows that it touched its highest point at $6.30 and its lowest point at $1.50 during that stretch. It currently has a 1-year price target of $6.14. Beta for the stock currently stands at 0.88.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NGEN was down-trending over the past week, with a drop of -2.09%, but this was up by 34.37% over a month. Three-month performance surged to 87.67% while six-month performance rose 104.73%. The stock gained 0.54% in the past year, while it has gained 168.10% so far this year. A look at the trailing 12-month EPS for NGEN yields -0.26 with Next year EPS estimates of -0.24. For the next quarter, that number is -0.04. This implies an EPS growth rate of 29.46% for this year and -31.49% for next year. EPS is expected to grow by 1.68% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 1.73%.
Float and Shares Shorts:
At present, 73.41 million NGEN shares are outstanding with a float of 62.23 million shares on hand for trading. In addition to Dr. Adam H. Rogers M.D. as the firm’s Chairman & Interim CEO, Dr. Harold Martin Punnett D.M.D. serves as its Co-Founder & Independent Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, NGEN reported revenue of $0.0 and operating income of -$6170687.0. The EBITDA in the recently reported quarter was -$8094284.0 and diluted EPS was -$0.06.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.21889 being high and -$0.21889 being low. For NGEN, this leads to a yearly average estimate of -$0.21889.
